Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 13, 2023

BUY
$26.2 - $36.08 $658,144 - $906,329
25,120 Added 250.7%
35,140 $944,000
Q2 2023

Aug 14, 2023

BUY
$25.16 - $41.38 $252,103 - $414,627
10,020 New
10,020 $357,000
Q3 2021

Nov 12, 2021

SELL
$58.38 - $84.96 $586,251 - $853,168
-10,042 Closed
0 $0
Q2 2021

Aug 10, 2021

BUY
$62.15 - $90.32 $411,557 - $598,099
6,622 Added 193.63%
10,042 $832,000
Q1 2021

May 11, 2021

BUY
$61.35 - $90.47 $209,817 - $309,407
3,420 New
3,420 $227,000
Q1 2020

May 08, 2020

SELL
$20.56 - $63.12 $532,956 - $1.64 Million
-25,922 Closed
0 $0
Q4 2019

Feb 04, 2020

BUY
$28.14 - $73.01 $729,445 - $1.89 Million
25,922 New
25,922 $1.64 Million

Others Institutions Holding ARWR

About ARROWHEAD PHARMACEUTICALS, INC.


  • Ticker ARWR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 105,849,000
  • Market Cap $2.07B
  • Description
  • Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...
More about ARWR
Track This Portfolio

Track Aigen Investment Management, LP Portfolio

Follow Aigen Investment Management, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Aigen Investment Management, LP, based on Form 13F filings with the SEC.

News

Stay updated on Aigen Investment Management, LP with notifications on news.